CoChat
Sign Up
Cited by 6Gastrointestinal motility and disordersAdvanced Drug Delivery SystemsInflammatory Bowel Disease

The DOI matches its Crossref record.

Targeted Delivery of Linaclotide to Specific Areas of The Intestine Affects Clinical Efficacy in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Chey, William D., Chamberlin, Paul, Bochenek, Wieslaw, Tripp, Kenneth, Higgins, Carolyn S., Omniewski, Nicholas, Fox, Susan M., Hall, Michael, Hashash, Ahmad, Miller, Matthew, O'Dea, Christopher R., Currie, Mark·2017·Gastroenterology
DOI 10.1016/s0016-5085(17)34374-3
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/s0016-5085(17)34374-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A preliminary RCT of targeted colonic delivery of linaclotide in patients with IBS-C demonstrated pain relief, without effects on constipation.

    “A preliminary RCT of targeted colonic delivery of linaclotide in patients with IBS-C demonstrated pain relief, without effects on constipation”

    From Irritable bowel syndrome (2020) · cites this paper as [145]

Citations

Cited by

Sorted by citations

Metadata

Authors
Chey, W. D., Chamberlin, P., Bochenek, W., Tripp, K., Higgins, C. S., Omniewski, N., Fox, S. M., Hall, M., Hashash, A., Miller, M., O'Dea, C. R., & Currie, M.
ORCID
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2017-04
Volume
152
Issue
5
Pages
S1314-S1315
ISSN
0016-5085 (ISSN-L)
DOI
10.1016/s0016-5085(17)34374-3
OpenAlex
W2607171225
Cited by
6
References
0
Citations by year
2020: 2 · 2019: 3 · 2017: 1
FWCI
1.73
Type
journal article
Language
en
Open access
closed
Licence
Locations
Gastroenterology (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
linaclotide, targeted drug delivery, irritable bowel syndrome with constipation, intestinal motility, clinical efficacy, guanylate cyclase-C agonist

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review